Postprandial Hyperglycemia In Type 2 Diabetes Therapeutics
1. Starlix patent expiration
Treatment: Use as a blood glucose-lowering agent; Use for treatment of diabetes, particularly type 2 diabetes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6641841 | NOVARTIS | Tablet composition |
Nov, 2017
(8 years ago) | |
| US5463116 | NOVARTIS | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
Oct, 2012
(13 years ago) | |
| US5488150 | NOVARTIS | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them |
Jan, 2013
(12 years ago) | |
| US6559188 | NOVARTIS | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
Sep, 2020
(5 years ago) | |
| US6844008 | NOVARTIS | Tablet composition |
Nov, 2017
(8 years ago) | |
| US6878749 | NOVARTIS | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
Sep, 2020
(5 years ago) | |
Drugs and Companies using NATEGLINIDE ingredient
Market Authorisation Date: 22 December, 2000
Dosage: TABLET
How can I launch a generic of STARLIX before it's drug patent expiration?
More Information on Dosage
STARLIX family patents
